Blog
Published October 14, 2022
Executive Summary
The “ANS rol” defines the minimum mandatory coverage of services (diagnostics, procedures, and treatments) in the private sector. While private providers could opt to provide coverage beyond this list, in practice, the “ANS rol” has traditionally been seen as the maximum coverage that would be provided with anything beyond the “ANS Rol” being typically rejected
Law 14.454/2022 published in September 2022 establishes that the “ANS Rol” will dictate the minimum coverage that private payers need to provide, but…
Read Now
Webinars
Available On Demand
Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets.
Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies that are less able to generate realistic valuations for complex innovative therapies. Using traditional valuation methods, we likely would not have seen the commercialization of…
Watch Now
White Papers
With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…
Read Now
Podcasts
The importance of ensuring diversity in clinical trials is undisputed, but barriers across the healthcare ecosystem still exist; what can healthcare regulators, policy makers, and manufacturers do to overcome challenges when recruiting clinical trial participants?
Host, Matthew Rube, a Senior Consultant at Trinity Life Sciences, joins two of the subject-matter experts that authored Trinity Life Sciences’ cornerstone white paper to discuss why ensuring diversity in clinical trials participation is such a critical issue, the results of the team’s research, and…
Listen Now
Webinars
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, now is the time to challenge conventional thinking.
We have all seen the dramatic shifts in scientific innovation in the life sciences industry that have been further accelerated by the COVID-19 pandemic. Despite these shifts, Trinity Life Sciences found that the commercial models employed by companies that launched new products recently were still largely based on traditional sales and marketing approaches.
In reaction to these findings, our experts…
Watch Now
Webinars
Available On Demand
What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products?
Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions.
In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.…
Watch Now
Webinars
Available On Demand
Demonstrating and communicating the value story to clinicians and payers is critical for successful commercialization, but there are many scenarios where new products may struggle to differentiate themselves. If you have a better mousetrap, how do you demonstrate value to support pricing, access, adoption and reimbursement?
The HEOR Evidence Strategy team at Trinity Life Sciences will conduct a webinar to explore this important question and share several case studies where we worked with companies facing this challenge. We will also…
Watch Now
Briefs
Patient Journey is a mainstay of pre-launch commercial insights generation, traditionally sitting beside demand estimation, segmentation and other key inputs to commercial decision-making and launch preparation.
Historically, Patient Journey has been used to identify leverage points and opportunities to increase market share for the new product. It has been generated through primary market research (largely qualitative) and presented as a one-time, standalone deliverable.
Today, the call to engage on a meaningful level with patients demands a new focus on the…
Read Now
Blog
Published September 6, 2022
Executive Summary
A series of new drug pricing reforms came into effect in Japan in April 2022, to encourage innovation and ensure the transparency and predictability of drug pricing in the future
These include updates to the cost-accounting pricing methodology, an expansion of the scope of the Price Maintenance Premium (PMP), an update to the spillover rule for drug re-pricing and an addition of a new “specific use” premium. Further details are outlined in the graphic below.
Summary of Japan’s…
Read Now
Webinars
Available On Demand
What do pharmaceutical manufacturers need to know to successfully navigate the market access landscape in China through the latest NRDL update?
The access landscape in China is rapidly evolving with important implications for novel medicines. The most recent update of China’s National Reimbursement Drug List (NRDL) in 2021 focused on the expansion of new and high-cost innovative therapies and highlighted the improving access environment for these drugs.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide…
Watch Now
